Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

Sep. 07, 2016

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of €1.0 billion aggregate principal amount of its 0.750% senior notes due 2024 and €600 million aggregate principal amount of its 1.375% senior notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively.

The issuance of the notes is expected to close on or about September 12, 2016, subject to customary closing conditions. The notes will pay interest on an annual basis.

Thermo Fisher intends to use the net proceeds of the offering to finance a portion of the estimated $4.2 billion purchase price for its acquisition of FEI Company and to pay certain associated costs. The FEI acquisition is expected to close by December 31, 2016, subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.

The joint book-running managers for the offering are J.P. Morgan Securities plc, Barclays Bank PLC, Mizuho International plc and Morgan Stanley & Co. International plc.

The offering is being made pursuant to an effective registration statement on Form S-3, as amended by the post-effective amendment thereto (including a prospectus), filed with the U.S. Securities and Exchange Commission (the “SEC”). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at Alternatively, Thermo Fisher, the underwriters or any dealer participating in this offering will arrange to send you the prospectus if you request it by calling J.P. Morgan Securities plc collect at +44 207-134-2468; by calling Barclays Bank PLC toll-free at 1-888-603-5847; by calling Mizuho International plc toll-free at +44 207-090-6929; or by calling Morgan Stanley & Co. International plc toll-free at 1-866-718-1649.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the company’s intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus and prospectus supplement dated September 7, 2016 related to the offering, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings,” and the documents incorporated by reference into the prospectus and prospectus supplement. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Source: Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

Media Contact Information:

Ron O’Brien, 781-622-1242


Investor Contact Information:

Ken Apicerno, 781-622-1294

Thermo Fisher Scientific At a Glance

More than $20 billion in annual revenue and

70,000 Employees

Premier Brands

– Thermo Scientific

– Applied Biosystems

– Invitrogen

– Fisher Scientific

– Unity Lab Services

Read more

NYSE: TMO (Common Stock)Jun 20, 2018 12:22 PM

Exchange NYSE (US Dollar)NYSE

Price 209.13

Change -0.80  (-0.38%)

Volume 321,773

% Change

Intraday High 210.50

52 Week High 226.44

Intraday Low 208.65

52 Week Low 170.18

Today's Open 210.00

Previous Close 209.93

Minimum 20 minute delay

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit

The world leader in serving science